ETF Securities expands talent pool amid market growth

Nov 19, 2018

ETF Securities expands talent pool amid market growth

SYDNEY, November 19 – ETF Securities today said it is continuing to expand its workforce and develop its product range in a market that is being strongly embraced by Australian investors.

“We are a growing business in a dynamic sector of the market. ETFs are the fastest growing product type in Australia, with funds under management posting annual growth of nearly 22 percent to more than $40 billion at the end of October,” said ETF Securities Australia Chief Executive Kris Walesby.

“Developing our talent pool is an important part of staying at the cutting edge of the industry,” Mr Walesby said.

British Olympian Larry Achike joins ETF Securities in the Business Development team after heading sales and business development at Surgicore Australia.

“I achieved the ultimate success in realising my goal and competing in two Olympic Games,” said Mr Achike. “But the pinnacle of my athletics career was being selected as the British Athletics team captain at the 2009 World Championships.”

“I am looking forward to channelling my competitive instincts into a sector leader like ETF Securities,” said the triple jump champion.

Mathew Knapman has also joined the ETF Securities team as an Assistant Portfolio Manager. He previously spent more than three years at Morningstar Australasia where he held various roles across data, operations and product.

Nicola Culey joined ETF Securities earlier this year and works across both the sales and research teams. She holds a Bachelor of Science (Honours) from the University of Sydney.

Amelia Serdoz was the Office Manager for ETFS’s London office, before coming on board at ETF Securities Australia only last month. Her responsibilities have expanded to incorporate a marketing analyst role.

ETF Securities now has a suite of 14 funds with funds under management of more than $1 billion.

Its latest launch was earlier this month when it brought to market Australia’s only pure-play healthcare biotechnology ETF (ASX code: CURE).

“The business has more than doubled its headcount since launching in 2015. I think that is testament to the fact that we are doing the right thing in the right part of the market,” said Mr Walesby.